SWTX icon

SpringWorks Therapeutics

57.40 USD
+2.27
4.12%
Updated Feb 12, 12:21 PM EST
1 day
4.12%
5 days
39.02%
1 month
55.09%
3 months
73.41%
6 months
54.93%
Year to date
59.09%
1 year
25.03%
5 years
72.37%
10 years
153.65%
 

About: SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Employees: 305

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

45% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 60

6% more funds holding

Funds holding: 207 [Q2] → 220 (+13) [Q3]

0.96% more ownership

Funds ownership: 107.71% [Q2] → 108.66% (+0.96%) [Q3]

14% less capital invested

Capital invested by funds: $3.01B [Q2] → $2.59B (-$420M) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]

51% less call options, than puts

Call options by funds: $4.46M | Put options by funds: $9.02M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$65
13%
upside
Avg. target
$74
28%
upside
High target
$78
36%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
David Nierengarten
37% 1-year accuracy
47 / 127 met price target
34%upside
$77
Outperform
Reiterated
12 Feb 2025
Evercore ISI Group
Cory Kasimov
38% 1-year accuracy
6 / 16 met price target
13%upside
$65
Outperform
Maintained
12 Feb 2025
HC Wainwright & Co.
Robert Burns
29% 1-year accuracy
49 / 167 met price target
29%upside
$74
Buy
Reiterated
12 Feb 2025
Guggenheim
Michael Schmidt
37% 1-year accuracy
10 / 27 met price target
36%upside
$78
Buy
Maintained
8 Jan 2025

Financial journalist opinion

Based on 7 articles about SWTX published over the past 30 days

Neutral
GlobeNewsWire
16 hours ago
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN   – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at:  https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks' MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1 With the approval, SpringWorks was granted a rare pediatric disease priority review voucher (PRV) by the FDA.
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Neutral
GlobeNewsWire
18 hours ago
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN   – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment resulted in robust ORR, deep and durable reductions in tumor volume, and a manageable safety profile – – SpringWorks granted rare pediatric disease priority review voucher by the FDA – Photos accompanying this announcement are available at:  https://www.globenewswire.com/NewsRoom/AttachmentNg/8eb8effc-49a5-4b24-911f-d3e6dfa9c8a9 https://www.globenewswire.com/NewsRoom/AttachmentNg/f1041678-3f79-43b7-a101-2390fb8cb86b https://www.globenewswire.com/NewsRoom/AttachmentNg/7d8cb318-e5f8-4944-8736-24cb19a5dec9 https://www.globenewswire.com/NewsRoom/AttachmentNg/072d748b-3237-48ad-8d83-1c6c23dda65f STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks' MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.1 With the approval, SpringWorks was granted a rare pediatric disease priority review voucher (PRV) by the FDA.
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
Positive
Reuters
20 hours ago
US FDA approves Springworks' genetic disorder drug
The U.S. Food and Drug Administration on Tuesday approved Springworks Therapeutics' drug to treat a type of rare genetic disorder that causes tumors to grow on nerves throughout the body.
US FDA approves Springworks' genetic disorder drug
Neutral
GlobeNewsWire
1 week ago
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates.
SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025
Negative
Zacks Investment Research
4 weeks ago
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
Neutral
GlobeNewsWire
4 weeks ago
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
– Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively  –
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
Positive
Seeking Alpha
4 weeks ago
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025.
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
Positive
Zacks Investment Research
1 month ago
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
Neutral
GlobeNewsWire
1 month ago
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT.
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
Seeking Alpha
1 month ago
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting.
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
Charts implemented using Lightweight Charts™